X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Faraday Pharmaceuticals
Deal Size: $134.7 million Upfront Cash: $2.7 million
Deal Type: Licensing Agreement April 13, 2021
Details:
Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nutritional therapies
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 26, 2021
Details:
Senda Biosciences has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BAM 15
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
Researcher at the Virginia Tech drug have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Disulfiram
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Treatment with disulfiram, normally prescribed to treat alcohol use disorder, shows health benefits in animal study.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
